NEW YORK (GenomeWeb News) — The flow of venture capital to the multivariate -omics disciplines slowed by more than a quarter in the first three months of 2007 compared to the same period in 2006, according to a GenomeWeb Daily News roundup of companies that disclosed receiving investments.
However, private equity financing to companies that sell or provide services for genomic or proteomic applications increased year over year.
VC investment in all privately held -omics companies covered by GenomeWeb Daily News fell nearly 26 percent to $63.2 million spread among five deals in the first quarter of 2007 from $79.6 million spread among nine deals in the same period last year.
But companies dealing in genomic wares saw a 138-percent increase in VC investment, netting $20.5 million in the first quarter of 2007 compared with $8.6 million year over year.
Also, investment in proteomic tool companies grew 150 percent to $48.7 million from $19 million in the first quarter last year.
Companies closing private-equity rounds in the first quarter of 2007 were Genizon BioSciences, AutoGenomics, Devgen, GenTel BioSciences, and Oxford Genome Sciences.
Companies closing private-equity rounds in the first quarter of 2006 were DeltaDot, BioTrove, Coda Genomics, Precision Therapeutics, Decision Biomarkers, EraGen, Intrexon, Guava Technologies, and Cetek.